CANVA
30.7.2024 05:31:28 CEST | Business Wire | Press release
Canva, a world leader in visual communication with more than 190 million monthly active users, today announced plans to acquire Leonardo.AI. As one of Australia’s fastest-growing startups, and a leading generative AI content and research company, Leonardo.AI is empowering millions of people to bring their ideas to life through production-quality images and videos. The acquisition complements Canva's offering and enhances the company’s vision to build a world-class suite of visual AI tools, marking this as an important milestone in its AI journey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729977410/en/
Canva will acquire Leonardo.AI, a leading generative AI content and research company (Graphic: Business Wire)
As AI continues to shape the future of work and visual communication, the acquisition will accelerate Canva’s investment in continued research and development while bringing Leonardo’s cutting-edge foundational model to Canva’s community worldwide. From creating assets for marketing and advertising campaigns, to visualizing stunning interior concepts, refining mockups, and producing dynamic videos, Leonardo’s technology has been used to produce more than one billion images in the last 18 months.
For Leonardo.AI this is an opportunity to produce new levels of AI innovation while also growing the organisation’s scale. With Canva’s support, the company’s current trajectory will be supercharged to build an even more creative-centric generative AI platform globally.
“We’re thrilled to welcome Leonardo.AI to Canva - two Australian companies joining forces to bring world-first breakthroughs in AI and creativity," said Cameron Adams, co-founder and Chief Product Officer of Canva. “This field is constantly evolving, and Leonardo’s technical leadership and community impact can’t be overstated. Bringing our worlds together will accelerate each of our teams' work, taking us from strength to strength, and we can’t wait to get started.”
World Leading Generative AI Capabilities
Founded in late 2022, Leonardo’s foundational model empowers millions of people to turn ideas into production-quality visual assets with unprecedented control, speed and style consistency. Creators can generate images in any chosen aesthetic in seconds with simple prompts, create videos, sketch with AI, and custom-train models with their own datasets.
Leonardo's new foundational model, Phoenix, takes creator control to the next level, with unprecedented prompt adherence, coherent, accurate text in images and the ability to generate production-ready assets in one shot.
“Today marks the start of a new chapter which will accelerate the pace we innovate at Leonardo.Ai,” said JJ Fiasson, Founder and CEO, Leonardo.AI. Joining the Canva family means we can invest more deeply in scaling our AI research efforts globally, and move even faster to deliver new features and functionality to creatives worldwide.”
In less than two years since launching, Leonardo.AI has amassed more than 19 million registered users and is used across a wide variety of industries including advertising, marketing, design, entertainment, architecture, fashion, e-commerce and education. The joint effort with Canva will produce new levels of AI technology to not only engage, but to also grow Leonardo’s fast growing user base.
From hobbyists to film directors, architects, and professional designers, Leonardo’s technology delivers advanced creative control that pushes the boundaries of what’s possible in generative AI, while remaining intuitive and accessible. Its models can generate stunning images in styles ranging from strikingly realistic photos to character portraits, anime, painterly styles, and more, while its AI video generation tools can bring almost any concept to dynamic life.
Reimagining Visual Communication
Canva’s recent Visual Economy Report shows that the need for effective, efficient, and compelling visual communication has surged dramatically. AI is now playing an increasingly important role in elevating both productivity and creativity at work. From marketing teams scaling global campaigns by instantly generating ad creative for specific audiences, to designers creating initial drafts and storyboards, generative artificial intelligence is changing the way work gets done.
Leonardo’s world-class technology and foundational model will supercharge Canva’s mission to empower every kind of professional to turn their ideas into designs in an instant, leading to faster, more innovative, and more compelling visual communication.
Leonardo's technology will complement Canva’s Magic Studio, the company’s suite of AI tools, which has been used more than 7 billion times since it launched in 2023. To date, Canva users have elevated their design and creative output leveraging Magic Studio for everything from summarising documents to creating images and turning brainstorm whiteboards into fully-fledged presentations.
Supercharging Canva’s AI Journey
Canva will continue to invest in Leonardo's standalone platform while integrating its technology throughout the company’s suite of Magic Studio products. Working with Leonardo’s team of 120 high-caliber researchers, engineers, and designers will also bolster Canva’s research and development capabilities as the company continues to invest in long-term innovation opportunities.
Acquisitions have played an important role in elevating and accelerating Canva’s technology over the last decade. The acquisition of Leonardo is the company’s 8th acquisition, joining Affinity (2024), Flourish (2022), Kaleido (2021), Smartmockups (2021), Pexels (2019), Pixabay (2019) and Zeetings (2018).
For more details about the acquisition, see Canva Co-Founder Cameron Adams blog post and Leonardo.Ai’s CEO JJ Fiasson’s blog post, respectively.
About Canva
Launched in 2013, Canva is a free online visual communications and collaboration platform with a mission to empower everyone in the world to design. Featuring a simple drag-and-drop user interface and a vast range of templates ranging from presentations, documents, websites, social media graphics, posters, apparel to videos, plus a huge library of fonts, stock photography, illustrations, video footage, and audio clips, anyone can take an idea and create something beautiful.
About Leonardo.Ai
Leonardo.Ai is one of Australia’s fastest-growing startups, democratising creativity with its generative AI content production platform. Since launching in 2022, the company has amassed more than 19 million users worldwide, who have generated over one billion images. Leonardo.Ai is currently being used by both hobbyists and professionals across creative industries such as advertising and marketing, design and architecture, film, fashion, photography, e-commerce, education, and more.
Downloadable Assets
Click here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729977410/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom